Abstract:Background:The efficacy of standard triple therapy for eradication of Helicobacter pylori(Hp)is decreasing in recent years,and bismuth-containing quadruple regimen becomes the first-line therapy for Hp infection. However,the application of bismuth has some limitations. Aims:To investigate the efficacy of proton pump inhibitor(PPI)-based standard triple therapy combined with teprenone for Hp eradication. Methods:A total of 155 Hp-infected chronic gastritis patients were enrolled from Jan. 2013 to Dec. 2014 at Aerospace Center Hospital,and were randomly assigned into standard triple therapy group,bismuth-containing quadruple therapy group and teprenone-containing quadruple therapy group. Patients in standard triple therapy group were given rabeprazole sodium 20 mg + amoxicillin and clavulanate potassium 914 mg +clarithromycin 500 mg bid for 10 days. Patients in bismuth-containing quadruple therapy group were given standard triple therapy combined with bismuth potassium citrate 0. 6 g bid for 10 days. Patients in teprenone-containing quadruple therapy group were given standard triple therapy combined with teprenone 50 mg bid for 10 days. Symptoms of patients were evaluated before and after eradication therapy. Four weeks after the end of therapy,13 C-urea breath test( UBT)was reexamined to assess the status of Hp infection. Results:One hundred and fifty-two patients completed the treatment course. By ITT analysis,the eradication rates of standard triple therapy group,bismuth-containing quadruple therapy group and teprenone-containing quadruple therapy group were 69. 8%(37 / 53),86. 5% (45 / 52)and 88. 0% (44 / 50), respectively;by PP analysis,the eradication rates of the three groups were 71. 2%(37 / 52),88. 2% (45 / 51)and 89. 8%(44 / 49),respectively. Eradication rates analyzed by ITT and PP in bismuth-containing quadruple therapy group and teprenone-containing quadruple therapy group were significantly higher than those in standard triple therapy group(P <0. 05),but no statistically significant difference was found between these two groups( P > 0. 05). Relieving rates of abdominal pain,abdominal distention and belching in bismuth-containing quadruple therapy group and teprenone-containing quadruple therapy group were higher than those in standard triple therapy group,but statistically significant difference was only found in relieving of abdominal pain between teprenone-containing quadruple therapy group and standard triple therapy group(88. 9% vs. 70. 3% ,P < 0. 05). Adverse effects included transient and mild nausea,diarrhea and black stool, etc. Conclusions:Teprenone-containing quadruple regimen are effective for Hp eradication and symptoms relieving with no severe adverse effects,the efficacy is comparable with bismuth-containing quadruple regimen.

Comparison of ranitidine bismuth citrate and lansoprazole-based regimens in the treatment of Helicobacter pylori infection

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Quadruple therapy of rabeprazole and ranitidine bismuth citrate for eradicating helicobacter pylori infection

Comparison of efficacy of different treatment regimens on H.Pylori Eradication

The Comparison of the Efficacy Between Esomeprazole Triple Therapy and Lansoprazol Triple Therapy for Eradication of Helicobacter Pylori

Efficacy of PPI-based Standard Triple Therapy Combined with Teprenone for Treatment of Helicobacter pylori Infection

Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of <i>Helicobacter pylori</i>

Efficacy of quadruple therapy containing probiotics on eradication of Helicobacter pylori

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori

Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial

The evaluation of the efficacy of pantoprazole-based triple and quadruple therapy in Helicobacter pylori eradication

High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.

Different Duration of Quadruple Therapy for First-line Helicobacter Pylori Eradication Treatment——A Randomized,Controlled Trial

Rabeprazole Combined with Clarithromycin and Amoxicillin in the Treatment of Helicobacter Pylori-Related Ulcer

Clinical Study on Berberine, Amoxicillin, Lansoprazole, Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in 283 Patients

[Efficacy of 4 Kinds of Triple Strategy for Helicobacter Pylori Eradication].

Comparison of the Efficacy of Triple Versus Quadruple Therapy on the Eradication of Helicobacter Pylori and Antibiotic Resistance.

A Clinical Study of Proton Pump Inhibitor-containing Quadruple Regimen as First-line Therapy for Helicobacter pylori Eradication

Efficacy of quadruple therapy and Lactobacillus acidophilus for Helicobacter pylori eradication

Influence of Pretreatment with Rabeprazole on Eradication Rate of Helicobacter pylori

Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial